Intravitreal Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration: Real-world Outcome of 12-week Extension After the Loading Dose from a UK Centre

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2024 Nov 20

PMID 39567706

Authors

Ashish Patwardhan

Nadir Ali

Stacey Law

Affiliations

Soon will be listed here.

Abstract

Objectives: To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).

Methods: A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1 September 2022 and 31 January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analysis, independent and Paired-sample T-tests were used to analyse the data.

Results: Sixty-eight eyes completed the one-year of treatment. The mean (SD) age was 79.9 (8.7) years and 61.8% were females. The mean (SD) number of injections at 52 weeks was 6.8 (0.8). The BCVA improved from baseline by a mean (SD) of 7.0 (10.8) letters at 12 weeks (p < 0.001), 7.3 (12.1) letters at 24 weeks (p < 0.001) and 8.2 (13.4) letters at 52 weeks (p < 0.001). The mean (SD) reduction in CST was 114.8 (SD 122.8) microns at 24 weeks (p < 0.001), and 89.4 (121.9) microns at 52 weeks (p < 0.001).

Conclusion: A Q12W approach following 4 loading doses of Faricimab for the treatment of nAMD in real-world achieves excellent visual outcomes comparable to pivotal trial with optimum number of injections in the first year.

References

Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H . Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023; 261(10):2945-2952. DOI: 10.1007/s00417-023-06116-y. View

Colijn J, Buitendijk G, Prokofyeva E, Alves D, Cachulo M, Khawaja A . Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017; 124(12):1753-1763. PMC: 5755466. DOI: 10.1016/j.ophtha.2017.05.035. View

Khanani A, Aziz A, Khan H, Gupta A, Mojumder O, Saulebayeva A . The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023; 37(17):3574-3581. PMC: 10686385. DOI: 10.1038/s41433-023-02553-5. View

Adamis A, Brittain C, Dandekar A, Hopkins J . Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond). 2020; 34(11):1966-1972. PMC: 7784857. DOI: 10.1038/s41433-020-0895-z. View

Bourne R, Jonas J, Flaxman S, Keeffe J, Leasher J, Naidoo K . Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol. 2014; 98(5):629-38. DOI: 10.1136/bjophthalmol-2013-304033. View

Khanani A, Guymer R, Basu K, Boston H, Heier J, Korobelnik J . TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2022; 1(4):100076. PMC: 9559073. DOI: 10.1016/j.xops.2021.100076. View

Pezzullo L, Streatfeild J, Simkiss P, Shickle D . The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018; 18(1):63. PMC: 5791217. DOI: 10.1186/s12913-018-2836-0. View

Heier J, Khanani A, Quezada Ruiz C, Basu K, Ferrone P, Brittain C . Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326):729-740. DOI: 10.1016/S0140-6736(22)00010-1. View

Wykoff C, Abreu F, Adamis A, Basu K, Eichenbaum D, Haskova Z . Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022; 399(10326):741-755. DOI: 10.1016/S0140-6736(22)00018-6. View

10.

Rush R, Rush S . Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2022; 16:4041-4046. PMC: 9747838. DOI: 10.2147/OPTH.S395279. View

11.

Owen C, Jarrar Z, Wormald R, Cook D, Fletcher A, Rudnicka A . The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012; 96(5):752-6. PMC: 3329633. DOI: 10.1136/bjophthalmol-2011-301109. View

12.

Cheng A, Joshi S, Banoub R, Saddemi J, Chalam K . Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration. Cureus. 2023; 15(6):e40100. PMC: 10328548. DOI: 10.7759/cureus.40100. View

13.

Stanga P, Valentin-Bravo F, Stanga S, Reinstein U, Pastor-Idoate S, Downes S . Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023; 37(15):3282-3289. PMC: 10564726. DOI: 10.1038/s41433-023-02505-z. View

14.

Leung E, Oh D, Alderson S, Bracy J, McLeod M, Perez L . Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2023; 17:1287-1293. PMC: 10167970. DOI: 10.2147/OPTH.S409822. View